REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026TRENDINGHexarelin: ↑↑ Surging ��� Trends score 100 as of May 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingEVENTpep-talk con ��� First US Peptide Convention · August 2026 · Anaheim CAFDAFDA advisory committee meetings scheduled: late July 2026REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026TRENDINGHexarelin: ↑↑ Surging ��� Trends score 100 as of May 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingEVENTpep-talk con ��� First US Peptide Convention · August 2026 · Anaheim CAFDAFDA advisory committee meetings scheduled: late July 2026

For research purposes only. Full disclaimer →

Research/Paper
Back to Research Library
PubMedRandomized Controlled TrialHuman Subjects

Responder Analyses from a Phase 2b Dose-Ranging Study of Bremelanotide.

Althof Stanley, Derogatis Leonard R, Greenberg Sally, Clayton Anita H, Jordan Robert, Lucas Johna, Spana Carl
The journal of sexual medicine2019DOI: 10.1016/j.jsxm.2019.05.012
bremelanotideHSDDFSAD

Quality Score

7/10

Citations

0

Subjects

Human

PeptideVault Analysis

Study Design

As a randomized controlled trial, this study represents the highest tier of clinical evidence. The randomized design controls for confounding variables, making causal inferences more robust than observational studies.

Our Assessment

Quality Assessment: 7/10 — This is a solidly conducted study with clear methodology and reasonable conclusions. Minor limitations exist (noted below) but don't undermine the core findings. The evidence here is reliable enough to inform both research direction and practical decision-making.

Findings in Context

The results for bremelanotide, HSDD, FSAD are encouraging. Critically, these findings come from human data — not animal models or in-vitro work — which makes them directly relevant to clinical applications. The study design adds significant weight to these conclusions.

On the Limitations

Every study has limitations, and being transparent about them is what separates good science from hype. These limitations don't invalidate the findings — they define the boundaries of what we can confidently conclude.

The Takeaway

Bottom line: This is high-quality human evidence for bremelanotide, HSDD, FSAD. If you're tracking the research landscape for these compounds, this paper deserves a close read.

Key Findings

The study found that bremelanotide at a dose of 1.75 mg demonstrated significant improvement in efficacy compared to placebo for premenopausal women with hypoactive sexual desire disorder (HSDD) and mixed HSDD/female sexual arousal disorder (FSAD), based on multiple responder analyses.

Limitations

The study's findings are limited by its phase 2b nature, which means further validation is needed through larger-scale phase 3 trials. Additionally, the analysis was restricted to a specific population of premenopausal women with HSDD and/or FSAD, limiting generalizability.

PeptideVault Analysis

Highlighting the clinical significance of responder analyses in determining the efficacy of bremelanotide for treating HSDD and FSAD.

bremelanotideHSDDFSAD

Bremelanotide Shows Promise in Treating Sexual Dysfunction: A Closer Look at Responder Analyses

Published: May 17, 2026 | Source: The journal of sexual medicine (2019) | Category: bremelanotide, HSDD, FSAD

Overview

A recent study published in The Journal of Sexual Medicine has provided valuable insights into the efficacy of bremelanotide for treating hypoactive sexual desire disorder (HSDD) and female sexual arousal disorder (FSAD). The research highlights the importance of responder analyses in clinical trials to determine meaningful improvements in patient-reported outcomes. This paper underscores the potential benefits of bremelanotide for premenopausal women suffering from these conditions.

Study Background

Prior to this study, there was a need for more robust data on effective treatments for HSDD and FSAD, particularly in identifying clinically significant changes that improve patients' quality of life. Bremelanotide is a melanocortin receptor agonist being investigated as a potential therapy for sexual dysfunction. This phase 2b dose-ranging study aimed to establish the minimal clinically important difference (MCID) for various patient-reported outcomes and assess bremelanotide's efficacy compared to placebo.

What the Research Found

The study involved premenopausal women with HSDD or mixed HSDD/FSAD, focusing on changes in sexual function over a period of treatment. Key findings include:

  • Significant improvements were observed at the 1.75 mg dose of bremelanotide for seven endpoints compared to placebo (P ≤ .03).
  • Responder rates indicated that patients experienced meaningful benefits based on multiple types of analyses, including those anchored to historical anchors and self-reported global benefit.
  • The results provided a basis for further clinical trials by identifying the MCID for various measures of sexual function.

What This Means for Peptide Users

For individuals considering bremelanotide as part of their treatment plan, these findings suggest that it may offer significant benefits in enhancing sexual desire and arousal. However, it is crucial to consult with a healthcare provider before starting any new therapy, especially given the specific population studied (premenopausal women) and the need for further validation through phase 3 trials.

Limitations and Caveats

While the study provides promising results, several limitations must be acknowledged:

  • The research was conducted on a relatively small sample size compared to what would be expected in larger-scale phase 3 studies.
  • The analysis is specific to premenopausal women with HSDD or FSAD, limiting its generalizability to other populations or conditions.
  • Further validation through additional clinical trials is necessary before broader recommendations can be made.

How This Compares to Previous Research

This study builds upon earlier research that established the potential of bremelanotide for treating sexual dysfunction. However, it provides a more detailed analysis by focusing on responder rates and clinically meaningful differences, which adds depth to our understanding of how this peptide might benefit patients in real-world settings.

Our Analysis

At PeptideVault, we view this study as an important step forward in the development of effective treatments for HSDD and FSAD. The use of multiple types of responder analyses strengthens the reliability of the findings. However, due to the limitations noted, it is essential that future research continues to explore bremelanotide's efficacy across broader populations.

Key Takeaways

  • Bremelanotide at a dose of 1.75 mg showed significant improvements in sexual function compared to placebo.
  • The study highlights the importance of responder analyses for subjective endpoints like those related to sexual health.
  • Further research is needed before definitive conclusions can be drawn about bremelanotide's efficacy and safety.

Original Source

Citation: Althof Stanley, Derogatis Leonard R, Greenberg Sally et al. (2019). Responder Analyses from a Phase 2b Dose-Ranging Study of Bremelanotide.. The journal of sexual medicine. DOI: 10.1016/j.jsxm.2019.05.012

Access: https://pubmed.ncbi.nlm.nih.gov/31277966/

---

This article is for informational and research purposes only. PeptideVault summarizes and analyzes published research. Always consult a licensed healthcare provider.

Editor's Note

This analysis was written by the PeptideVault research team to make complex findings accessible to the peptide community. We encourage readers to review the source paper for full methodology and data. For more on bremelanotide, explore our research guides.

Citation

Althof Stanley, Derogatis Leonard R, Greenberg Sally et al.. (2019). Responder Analyses from a Phase 2b Dose-Ranging Study of Bremelanotide.. The journal of sexual medicine. https://doi.org/10.1016/j.jsxm.2019.05.012

View full text on PubMed

This content is derived from peer-reviewed research for educational purposes only. It does not constitute medical advice. Always consult a qualified healthcare provider before using any peptide-based therapy.